July 6, 2015

The focus on education at McKesson’s ideaShare 2015 didn’t stop when the exhibit hall opened Thursday evening. Friday and Saturday in San Diego saw a robust lineup of Continuing Education and Lunch & Learn sessions that aimed to keep independent pharmacy owners and pharmacists apprised of the latest developments in patient care and the current state of the business.

February 26, 2015

Sanofi expands its portfolio of insulin therapy products with the introduction of the once-daily, long-acting Toujeo. 

February 3, 2015

Afrezza, an inhaled insulin powder, is now available by prescription in U.S. retail pharmacies, Sanofi and MannKind Corp. announced. The drug is approved by the Food and Drug Administration to control high blood sugar in adults who have type 1 and type 2 diabetes.

 

November 10, 2014

Eli Lilly and Co. on Monday announced that its Type 2 diabetes treatment drug Trulicity (dulaglutide) , is now available in U.S. pharmacies. The drug is a once-weekly glucagon-like peptide-1 receptor agonist, and comes in a single-dose pen, which doesn't require the patient to mix, measure or handle the needle, the company said.

September 26, 2014

Camber Pharmaceuticals announced the launch of raloxifene hydrochloride, USP tablets in 60-mg dosage strengths.

September 19, 2014

The Food and Drug Administration on Thursday approved Trulicity (dulaglutide), a once-a-week injection to improve blood-sugar levels in adults with Type 2 diabetes. 

August 26, 2014

Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Co. announced that Jardiance (empagliflozin) tablets are now available by prescription in pharmacies across the United States.

August 19, 2014

The Food and Drug Administration has granted tentative approval for Basaglar (insulin glargine injection), which is used to improve glycemic control in adults with Type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with Type 1 diabetes.

August 11, 2014

Sanofi on Monday acquired the rights to Afrezza Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with Type 1 and Type 2 diabetes, from MannKind in a deal that could be worth as much as $925 million. 

August 8, 2014

The Food and Drug Administration earlier this week announced approval for Orbactiv (oritavancin), an antibacterial drug used to treat patients with acute bacterial skin and skin structure infections.

June 30, 2014

Afrezza, an inhaled insulin powder meant to treat diabetes patients, was approved Friday by the Food and Drug Administration.

June 27, 2014

Dr. Reddy's Labs on Friday announced the launch of duloxetine delayed-release capsules USP in 20 mg, 30 mg and 60 mg dosage strengths.

June 19, 2014

Novo Nordisk on Thursday announced the launch of Levemir FlexTouch (insulin detemir [rDNA origin] injection), a prefilled insulin delivery mechanism, providing a new way for diabetics to administer their insulin.

June 12, 2014

A study published Wednesday on JAMA's website found that diabetes patients taking metformin had a higher risk of all-cause death when insulin was added to their treatment as compared to when sulfonylureas were added to treatment.

May 28, 2014

Sanofi and Eli Lilly and Co. on Wednesday announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil).

May 27, 2014

Aurobindo Pharma on May 15 gained approval to produce a generic version of olanzapine orally disintegrating tablets in 5-mg, 10-mg, 15-mg and 20-mg strengths.

May 14, 2014

Mylan on Wednesday announced that it has launched olanzapine orally disintegrating tablets in 5-mg, 10-mg, 15-mg and 20-mg strengths. The drug is the generic version of Zyprexa Zydis tablets from Eli Lilly and Co.

April 22, 2014

Eli Lilly on Monday announced that the Food and Drug Administration has approved Cyramza (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.

April 10, 2014

Lupin announced that it received final approval from the Food and Drug Administration for pioglitazone tablets USP in 15-mg, 30-mg and 45-mg strengths.

April 3, 2014

MannKind Corp. on Tuesday announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration voted 13-to-1 to recommend that Afrezza (insulin human [rDNA origin]) inhalation powder be granted marketing approval by the FDA to improve glycemic control in adults with Type 1 diabetes and voted 14-to-0 to recommend that Afrezza be granted marketing approval by the FDA to improve glycemic control in adults with Type 2 diabetes.

April 1, 2014

Prasco Labs on Tuesday announced that it has signed a marketing and distribution agreement with Eli Lilly and Co. to market the authorized generic version of Evista (raloxifene hydrochloride tablets), 60 mg strength, in the United States.

April 1, 2014

Teva Pharmaceuticals on Tuesday announced the introduction and availability of Raloxifene hydrochloride tablets, USP.

March 4, 2014

Teva Pharmaceutical Industries announced that it received approval for generic Evista (raloxifene) tablets, 60-mg, in the United States.

March 3, 2014

AstraZeneca received approval from the Food and Drug Administration for its Bydureon pen (exenatide extended-release for injectable suspension) 2-mg, which is to be used as an addition to diet and exercise to improve glycemic control in adults with Type 2 diabetes.